<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4330</id>
  <title>T3D4276</title>
  <common-name>Adenosine triphosphate</common-name>
  <description>Adenosine triphosphate (ATP) is a nucleotide consisting of a purine base (adenine) attached to the first carbon atom of ribose (a pentose sugar). Three phosphate groups are esterified at the fifth carbon atom of the ribose. ATP is incorporated into nucleic acids by polymerases in the processes of DNA replication and transcription. ATP contributes to cellular energy charge and participates in overall energy balance, maintaining cellular homeostasis. ATP can act as an extracellular signaling molecule via interactions with specific purinergic receptors to mediate a wide variety of processes as diverse as neurotransmission, inflammation, apoptosis, and bone remodelling. Extracellular ATP and its metabolite adenosine have also been shown to exert a variety of effects on nearly every cell type in human skin, and ATP seems to play a direct role in triggering skin inflammatory, regenerative, and fibrotic responses to mechanical injury, an indirect role in melanocyte proliferation and apoptosis, and a complex role in Langerhans cell-directed adaptive immunity. During exercise, intracellular homeostasis depends on the matching of adenosine triphosphate (ATP) supply and ATP demand. Metabolites play a useful role in communicating the extent of ATP demand to the metabolic supply pathways. Effects as different as proliferation or differentiation, chemotaxis, release of cytokines or lysosomal constituents, and generation of reactive oxygen or nitrogen species are elicited upon stimulation of blood cells with extracellular ATP. The increased concentration of adenosine triphosphate (ATP) in erythrocytes from patients with chronic renal failure (CRF) has been observed in many studies but the mechanism leading to these abnormalities still is controversial.  (A3367, A3368, A3369, A3370, A3371).</description>
  <cas>56-65-5</cas>
  <pubchem-id>5957</pubchem-id>
  <chemical-formula>C10H16N5O13P3</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point>176°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility>1E+006 mg/L</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure nil="true"/>
  <target nil="true"/>
  <mechanism-of-toxicity>ATP is able to store and transport chemical energy within cells. ATP also plays an important role in the synthesis of nucleic acids. ATP can be produced by various cellular processes, most typically in mitochondria by oxidative phosphorylation under the catalytic influence of ATP synthase. The total quantity of ATP in the human body is about 0.1 mole. The energy used by human cells requires the hydrolysis of 200 to 300 moles of ATP daily. This means that each ATP molecule is recycled 2000 to 3000 times during a single day. ATP cannot be stored, hence its consumption must closely follow its synthesis.</mechanism-of-toxicity>
  <metabolism>Metabolism of organophosphates occurs principally by oxidation, by hydrolysis via esterases and by reaction with glutathione. Demethylation and glucuronidation may also occur.  Oxidation of organophosphorus pesticides may result in moderately toxic products.  In general, phosphorothioates are not directly toxic but require oxidative metabolism to the proximal toxin.  The glutathione transferase reactions produce products that are, in most cases, of low toxicity. Paraoxonase (PON1) is a key enzyme in the metabolism of organophosphates. PON1 can inactivate some organophosphates through hydrolysis. PON1 hydrolyzes the active metabolites in several organophosphates insecticides as well as, nerve agents such as soman, sarin, and VX. The presence of PON1 polymorphisms causes there to be different enzyme levels and catalytic efficiency of this esterase, which in turn suggests that different individuals may be more susceptible to the toxic effect of organophosphate exposure.</metabolism>
  <toxicity>Oral LD&lt;sub&gt;50&lt;/sub&gt; in rats is &gt; 2 g/kg.</toxicity>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>For nutritional supplementation, also for treating dietary shortage or imbalance</use-source>
  <min-risk-level nil="true"/>
  <health-effects nil="true"/>
  <symptoms nil="true"/>
  <treatment nil="true"/>
  <created-at type="dateTime">2014-08-29T06:12:10Z</created-at>
  <updated-at type="dateTime">2026-05-14T16:24:27Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Adenosine_triphosphate</wikipedia>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C00002</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id>15422</chebi-id>
  <biocyc-id>ATP</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB00171</drugbank-id>
  <pdb-id>ATP</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>NC1=NC=NC2=C1N=CN2[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O</moldb-smiles>
  <moldb-formula>C10H16N5O13P3</moldb-formula>
  <moldb-inchi>InChI=1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1</moldb-inchi>
  <moldb-inchikey>ZKHQWZAMYRWXGA-KQYNXXCUSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">507.181</moldb-average-mass>
  <moldb-mono-mass type="decimal">506.995745159</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>-5.5</logp>
  <hmdb-id>HMDB00538</hmdb-id>
  <chembl-id>CHEMBL14249</chembl-id>
  <chemspider-id>5742</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;George M. Whitesides, Patricia E. Garrett, Merrell G. Siegel, &amp;#8220;Method for preparing adenosine triphosphate.&amp;#8221; U.S. Patent US4164444, issued April, 1975.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM003236</chemdb-id>
  <dsstox-id>DTXSID6022559</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00013346</susdat-id>
  <iupac>({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid</iupac>
  <moldb-polar-surface-area>279.13</moldb-polar-surface-area>
  <moldb-refractivity>95.81429999999999</moldb-refractivity>
  <moldb-polarizability>38.917323034745216</moldb-polarizability>
  <moldb-rotatable-bond-count>8</moldb-rotatable-bond-count>
  <moldb-acceptor-count>14</moldb-acceptor-count>
  <moldb-donor-count>7</moldb-donor-count>
  <moldb-pka-strongest-acidic>0.895367248482958</moldb-pka-strongest-acidic>
  <moldb-pka-strongest-basic>4.0142158810282655</moldb-pka-strongest-basic>
  <moldb-physiological-charge>-3</moldb-physiological-charge>
  <moldb-number-of-rings>3</moldb-number-of-rings>
  <moldb-alogps-logp>-0.84</moldb-alogps-logp>
  <moldb-alogps-logs>-2.05</moldb-alogps-logs>
  <moldb-alogps-solubility>4.49e+00 g/l</moldb-alogps-solubility>
</compound>
